Tiragolumab ELISA Kit (DS739018)

Fiche technique Partager le produit Copier les informations

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	DS739018
Description	Tiragolumab ELISA Kit (DS739018) — Quantitative sandwich ELISA for Tiragolumab. Sample: Plasma, Serum. Range: 31.25 ng/mL - 2000 ng/mL. Highlights ●Sandwich Format — High specificity, reliable quantification. ●Ready-to-Use — Complete kit with pre-coated plates included.
Type d'échantillon	Plasma, Serum
Plage	31.25 ng/mL - 2000 ng/mL
Numéro d'accès	Q495A1
Applications	ELISA
Méthode de détection	Colorimetric
Type de test	Quantitative
Retraitement	75-110%
Expédition	2-8 ℃
Stabilité et stockage	When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃.
Spécifications	Tiragolumab
Noms alternatifs	MTIG-7192-A, MTIG-7192A, MTIG7192A, RG-6058, RO-7092284, RO7092284, 1918185-84-8
Contexte	T-cell immunoreceptor with Ig and ITIM domains (Tiragolumab) is a ~26 kDa protein. Inhibitory receptor that plays a role in the modulation of immune responses. Suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. Upon binding to its ligands PVR/CD155 or NECTIN2/CD112, which are expressed on antigen-presenting cells, sends inhibitory signals to the T-cell or NK cell. Mechanistically, interaction with ligand leads to phosphorylation of the cytoplasmic tail by Src family tyrosine kinases such as FYN or LCK, allowing subsequent binding to adapter GRB2 and SHIP1/INPP5D. In turn, inhibits PI3K and MAPK signaling cascades. 1. Yu, X. et al. (2009) Nature immunology 10, 48-57. PMID: 19011627 2. Liu, S. et al. (2013) Cell death and differentiation 20, 456-64. PMID: 23154388 3. Li, M. et al. (2014) The Journal of biological chemistry 289, 17647-57. PMID: 24817116 4. Reches, A. et al. (2020) Journal for immunotherapy of cancer 8. PMID: 32503945
Note	For Research Use Only.